Reports Q3 revenue $3.989M, consensus $5.8M. “Tonix expects topline results from its Phase 3 fibromyalgia study and Phase 2 chronic migraine study before year end,” said Seth Lederman, M.D., Chief Executive Officer of Tonix. “The Phase 3 RESILIENT trial in fibromyalgia, if successful, is expected to be the final efficacy trial required for submitting a New Drug Application for approval by the U.S. Food and Drug Administration for TNX-102 SL. In the Phase 2 proof-of-concept PREVENTION study in chronic migraine of TNX-1900, all patients have completed their final visit and topline results are expected in early December 2023.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TNXP:
- Tonix Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Highlights
- TNXP Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Tonix Pharmaceuticals’ TNX-1800 selected by NIH/NIAID Project NextGen
- Tonix Pharmaceuticals’ Vaccine Candidate, TNX-1800, Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials
- Tonix Pharmaceuticals trading resumes